Revenue minus Pfizer ~150k, including Janssen payments.this...

Revenue minus Pfizer ~150k, including Janssen payments.

this means no real growth across the combined commercial portfolio of Sleepcheck and Dx. This is my main concern as a potential shareholder (seriously, I don't care who holds, buys, votes yes or no)... There is no transparency around usage and uptake from DX partners.

so why would one get excited by Medgate extension if they're not really delivering much to begin with?

all interesting points. I haven't read anything else, just that revenue figure. All my opinion...